Dihydroergotamine mesylate (DHE) is under clinical development by Amneal Pharmaceuticals and currently in Pre-Registration for Cluster Headache Syndrome (Cluster Headache). According to GlobalData, Pre-Registration drugs for Cluster Headache Syndrome (Cluster Headache) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Dihydroergotamine mesylate (DHE)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dihydroergotamine mesylate (DHE) overview

Dihydroergotamine mesylate is under development for the treatment of migraine and cluster headaches. The drug candidate is administered through prefilled syringe autoinjector (dihydroergotamine (DHE) autoinjector) and acts by targeting 5-hydroxytryptamine receptor 1D (5 HT1D).

Amneal Pharmaceuticals overview

Amneal Pharmaceuticals (Amneal), formerly Amneal Pharmaceuticals, is a pharmaceutical company that develops, manufactures, markets and distribute pharmaceutical drug. It offering products includes generic and specialty pharmaceutical products. The company also offers product such as Activella, Albenza, Dexedrine, Nizatidine Oral Solution and Pyridiu in the area of oncology, inflammation and pain, central nervous system disorders, endocrinology and parasitic infections. Amneal offers products in various dosage forms such as oral solids and liquids, injectables, topicals, creams and ointments, transdermals, inhalation, ophthalmic and otic liquids and other device driven products. The company has operational presence in India, Switzerland, Ireland and the U.K. Amneal is headquartered in Bridgewater, New Jersey, the US.

For a complete picture of Dihydroergotamine mesylate (DHE)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.